ANALYSIS OF RISK FACTORS AND TREATMENT PHASES ON THE SEVERITY OF HEPATOTOXICITY DUE TO ANTI-TUBERCULOSIS DRUGS
DOI:
https://doi.org/10.36387/jiis.v11i1.2911Keywords:
Lung disease, Anti-tuberculosis drugs, Liver function impairment, Side effects, Risk factorsAbstract
Hepatotoxicity caused by anti-tuberculosis drugs (OAT) is one of the adverse effects of tuberculosis therapy and may lead to liver dysfunction. This study aimed to analyze the relationship between age, gender, and treatment phase with the severity of OAT induced hepatotoxicity, as well as to assess factors influencing the increase in hepatotoxicity grade. This research employed a retrospective cross-sectional design and was conducted at Ulin Regional Hospital Banjarmasin using a total sampling method involving 45 tuberculosis patients. Secondary data were obtained from medical records of TB patients in 2024–2025. The results showed that 62.2% of patients were under 60 years old and 37.8% were over 60 years old. Male patients accounted for 75.6%, while females accounted for 24.4%. The distribution of hepatotoxicity grades was 40% normal, 28.9% grade 1, 20% grade 2, and 11.1% grade 3. Based on the treatment phase, 91.1% of patients were in the intensive phase and 8.9% were in the continuation phase. The Chi square test revealed no significant association between age, gender, or treatment phase and the severity of hepatotoxicity.
References
Adhanty, S., & Syarif, S. (2023). Kepatuhan Pengobatan pada Pasien Tuberkulosis dan Faktor-Faktor yang Mempengaruhinya: Tinjauan Sistematis. Jurnal Epidemiologi Kesehatan Indonesia, 7(1). https://doi.org/10.7454/epidkes.v7i1.6571
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019). EASL Clinical Practice Guidelines: Drug-induced liver injury. Journal of Hepatology, 70(6), 1222–1261. https://doi.org/10.1016/j.jhep.2019.02.014
Bawonte, T. G., Mambo, C. D., & Masengi, A. S. R. (2021). Faktor-Faktor yang mempengaruhi Tuberculosis Multidrug Resistance (MDR-TB). EBiomedik, 9(1), 117–125. https://doi.org/10.35790/ebm.9.1.2021.31949
Clarasanti, I., Wongkar, M., & Waleleng, B. J. (2016). Gambaran enzim transaminase pada pasien tuberkulosis paru yang diterapi dengan obat-obat anti tuberkulosis di RSUP Prof. Dr. R.D. Kandou Manado. Jurnal E-Clinic (ECl), 4(1), 1–6.
Dasuki, A., Muti, A. F., & Yusmaini, H. (2020). Faktor Resiko Kejadian Peningkatan Kadar Transminase pada Penggunaan Obat Antituberkulosis Pasien Tuberkulosis Paru di RST Wijayakusuma Purwakerto. Jurnal Farmasi Indonesia, 12.
Wahyudi, A. D., & Soedarsono. (2015). Farmakogenomik Hepatotoksisitas Obat Anti Tuberkulosis. Respirasi, 1, 103–108.
Mahartati, N. M. N., & Syarif, S. (2024). Risk Factors of Treatment Failure among Pulmonary Tuberculosis Patients: Systematic Review. Media Publikasi Promosi Kesehatan Indonesia, 7(4), 899–906. https://doi.org/10.56338/mppki.v7i4.5157
Permata Sari, D., & Andriani, V. (2024). Kajian Hubungan Penggunaan Obat Antituberkulosis Fase Awal Terhadap Kadar Sgot-Sgpt Pada Pasien Tbc Paru Di Rsud Pasar Rebo Jakarta. Jurnal Kesehatan Tambusai, 5(4), 10783–10792.
Rifai, A., Herlianto, B., Mustika, S., Pratomo, B., & Supriono. (2015). Insiden dan Gambaran Klinis Hepatitis Akibat Obat Anti Tuberkulosis di Rumah Sakit Umum Daerah Dr. Saiful Anwar Malang. Jurnal Kedokteran Brawijaya, 28(3), 238–241.
Safira, Z., Sudarwati, S., & Alam, A. (2018). Profil Pasien Tuberkulosis Anak dengan Anti-tuberculosis Drug Induced Hepatotoxicity di Rumah Sakit Umum Pusat Dr. Hasan Sadikin Bandung. Sari Pediatri, 19(5), 290–294.
Deliananda, S. S., & Azizah, R. (2022). Faktor Resiko Kejadian Tuberkulosis Paru di Indonesia Tahun 2014-2021 : Literature Review. Media Publikasi Promosi Kesehatan Indonesia, 5(9), 1054–1062. https://doi.org/10.31934/mppki.v2i3
Sandi, D. A. D., Nurrahma, I. M., & Isnani, N. (2025). Karakteristik Pasien TB Resisten Obat di Kalimantan Selatan: Studi Korelasi terhadap Kesiapan Implementasi Regimen BPaL/M. Borneo Journal of Pharmascientech, 09, 247–258. https://doi.org/10.59053/bjp.v9i2.738
Wang, N., Chen, X., Hao, Z., Guo, J., Wang, X., Zhu, X., Yi, H., Wang, Q., & Tang, S. (2022). Incidence and Temporal Trend of Antituberculosis Drug-Induced Liver Injury: A Systematic Review and Meta-Analysis. Journal of Tropical Medicine, 2022. https://doi.org/10.1155/2022/8266878
Wardhana, M. F., Milanda, T., & Sumiwi, S. A. (2018). Assessment of Risk Factors of Hepatotoxicity among Tuberculosis Patients. Pharmacology and Clinical Pharmacy Research, 3(1). https://doi.org/10.15416/pcpr.v3i1.16450
Wiyati, T., Irawati, D., & Budiyono, I. I. (2014). Studi Efek Samping Obat Dan Penanganannya Pada Pasien Tb Paru Di Puskesmas Melong Asih, Cimahi. JSTFI Indonesian Journal of Pharmaceutical Science and Technology, III(1).
Zhao, H., Wang, Y., Zhang, T., Wang, Q., & Xie, W. (2020). Drug-induced liver injury from anti-tuberculosis treatment: A retrospective cohort study. Medical Science Monitor, 26. https://doi.org/10.12659/MSM.920350
Downloads
Published
Issue
Section
License
Copyright (c) 2026 JIIS (Jurnal Ilmiah Ibnu Sina): Ilmu Farmasi dan Kesehatan
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
